Who Paid My Doc
Arpit Rao
Hematology & Oncology Minneapolis, MN Medical Doctor
NPI 1982991170 CMS profile 1381873
909 Fulton St Se, Minneapolis, MN 55455
General payments
$46,118
Research payments
$14,633
Ownership & investment interest
$0
Research they led as principal investigator
$1,537,953
Through program year 2025, Arpit Rao of Minneapolis, MN is reported in the CMS Open Payments database as having received $46,118 across 65 general payments and $14,633 in research payments paid to them. Separately, studies naming them as principal investigator received $1,537,953 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $77 | 1 | |
| 2024 | General | $140 | 1 | |
| 2023 | General | $18,165 | 18 | |
| 2022 | General | $5,987 | 12 | |
| 2021 | General | $13,055 | 9 | |
| 2020 | General | $4,574 | 4 | |
| 2019 | General | $4,119 | 20 | |
| 2019 | Research | $14,633 | 2 |
Beside peers
- Arpit Rao
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Arpit Rao were reported at $77. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Arpit Rao | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,119 | $529 | $121–$2,516 | $163 |
| 2020 | $4,574 | $339 | $82–$2,213 | $114 |
| 2021 | $13,055 | $263 | $49–$1,965 | $132 |
| 2022 | $5,987 | $416 | $103–$2,395 | $149 |
| 2023 | $18,165 | $542 | $125–$2,646 | $160 |
| 2024 | $140 | $692 | $141–$3,008 | $164 |
| 2025 | $77 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
11
Drug cost
$43
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Prednisone | Generic | 11 | $43 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
67 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Hematology & Oncology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.